Rupert Bartsch

Sep 24, 2024 | medscape.com | Sara M. Tolaney |Rupert Bartsch |Carmen Criscitiello

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. In recent years, there have been significant advancements in the treatment of HER2+ metastatic breast cancer (MBC), broadening the array of available therapeutic options. However, navigating the complexities of selecting the optimal sequence for HER2 targeted therapies remains challenging.

Jan 4, 2024 | onclive.com | Rupert Bartsch

January 4, 2024Rupert Bartsch, MD, discusses findings from the final analysis of the phase 2 TUXEDO-1 trial of trastuzumab deruxtecan in patients with HER2-positive breast cancer with active brain metastases.

Feb 23, 2023 | cancertreatmentreviews.com | Volkmar Müller |Rupert Bartsch |Nancy Lin |Filippo Montemurro

Monoclonal antibodyNCT01004172*[54]Leone J.P. Emblem K.E. Weitz M. Gelman R.S. Schneider B.P. Freedman R.A. et al. Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Phase 2, single-arm, open-label trialBevacizumab (monotherapy 15 mg/kg IV on cycle 1 day 1) + carboplatin (IV, AUC = 5, on cycle 1 day 8; HER2– cohort only). Patients with HER2-positive disease also received trastuzumab (8 mg/kg load if indicated; otherwise, 6 mg/kg on cycle 1 day 8).